2022 annual financial data
Inhibikase Therapeutics 2022 Revenue growth
Direct answer
Revenue growth was -96.02%.
Operating income was -18,128,608 USD and net income was -18,054,155 USD.
Operating cash flow was -17,351,103 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 123,440 USD
- Operating income
- -18,128,608 USD
- Net income
- -18,054,155 USD
- Operating cash flow
- -17,351,103 USD